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Rheumatoid arthritis (RA) is a chronic inﬂammatory disease aﬀecting the joints that can lead to deformities and disability.
The prolonged use of conventionally used drugs is associated with severe adverse reactions. Therefore, safer and less expensive
therapeutic products are continually being sought. Huo-Luo-Xiao-Ling dan (HLXL), a traditional Chinese herbal mixture, and
its modiﬁed versions possess anti-arthritic activity. In this paper, we examined the inﬂuence of modiﬁed HLXL on two of the key
mediators of arthritic inﬂammation and tissue damage, namely, chemokines and matrix-metalloproteinases (MMPs) in the rat
adjuvant-induced arthritis (AA) model of RA. We treated arthritic Lewis rats with HLXL (2.3g/kg) by daily gavage beginning at
the onset of AA. The control rats received the vehicle. At the peak phase of AA, rats were sacriﬁced and their draining lymph node
cells (LNC) and spleen adherent cells (SAC) were tested. The HLXL-treated rats showed a signiﬁcant reduction in the levels of
chemokines (RANTES, MCP-1, MIP-1α, and GRO/KC), MMPs (MMP 2 and 9), as well as cytokines (IL-6 and IL-17) that induce
them, compared to the control vehicle-treated rats. Thus, HLXL controls arthritis in part by suppressing the mediators of immune
pathology, and it might oﬀer a promising alternative/adjunct treatment for RA.
1.Introduction
Rheumatoid arthritis (RA) is a chronic debilitating auto-
immune disease that aﬀects over 1 percent of the popu-
lation worldwide [1]. The commonly used drugs such as
nonsteroidal anti-inﬂammatory drugs (NSAIDS) and bio-
logics (e.g., antitumor necrosis-α antibody) are eﬀective in
alleviating the symptoms of the disease. However, the pro-
longed use of these drugs is associated with severe adverse
reactions [2, 3]. In addition, these drugs are expensive, and
not all patients respond well to them. In view of these lim-
itations, it is essential to continue the search for safer and
less expensive alternatives to the conventionally used drugs
[4, 5]. Natural plant products represent a promising group
of therapeutic agents for arthritis. However, one of the
major concerns in seriously considering these products for
therapeutic purposes is that the mechanisms of action of
many of them are poorly deﬁned, if at all.
RA primarily targets the joints, and is characterized
by inﬂammatory synovitis mediated by leukocytes and the
proinﬂammatory cytokines secreted by them [1, 6]. The
migration of leukocytes from the peripheral blood into the
joints is directed by chemotactic cytokines (chemokines) [7].
Furthermore, severe arthritis is associated with cartilage and
bone damage, which is mediated in part by the matrix-
degrading enzymes, matrix metalloproteinases (MMPs) [8,
9]. Therefore, chemokines and MMPs are attractive targets
for the treatment of arthritis [10, 11].2 Evidence-Based Complementary and Alternative Medicine
Chemokines are small, biologically active molecules
that attract speciﬁc populations of inﬂammatory cells and
regulate their traﬃcking to the site of inﬂammation. Among
the chemokines that play an important role in inﬂammation,
including RA, are regulated upon activation, normal T cell
expressed, and secreted (RANTES), also known as chemok-
ine C-C motif ligand 5 (CCL5); monocyte chemotactic
protein-1 (MCP-1), or CCL2; macrophage inﬂammatory
protein-1α (MIP-1α), or CCL3; and growth regulated onco-
gene-keratinocyte chemoattractant (GRO/KC), or chemok-
ineC-X-C motif ligand1(CXCL1) [12–15].Thechemokines
interact with their receptors which belong to seven-
transmembrane G-protein-coupled molecules. Henceforth,
for simplicity we will refer to the 4 chemokines tested in this
study by their common names (RANTES, MCP-1, MIP-1α,
and GRO/KC).
MMPs are a group of zinc-dependent endopeptidases
that can degrade the extracellular matrix (ECM). Among the
MMPs, MMP-2 (gelatinase A) and MMP-9 (gelatinase B)
are especially important in collagen degradation [16]. The
expression/activity of MMPs can be modulated by the proin-
ﬂammatory cytokines interlukin-6 (IL-6) and IL-17 that are
expressed in the synovial tissue and synovial ﬂuid in the
joints of RA patients [8, 17].
Huo-luo-xiao-ling dan (HLXL), a traditional Chinese
herbal formula, and its modiﬁed versions have been used in
folk medicine over centuries to treat inﬂammatory arthritis
or joint pain, referred to as the “Bi syndrome”[ 18, 19]. The
use of a combination of multiple herbs is designed to exploit
the additive or synergistic activities of individual herbs, as
well as to balance or neutralize the toxic eﬀects of certain
herbal components by others in the mixture [20]. In our pre-
vious studies in animal models of arthritis, we have shown
that oral administration of modiﬁed HLXL, a well-charac-
terized herbal mixture [21–23], to rats can attenuate inﬂam-
matorypawedemaaswellastheswellingandpainassociated
with clinical arthritis. In addition, HLXL modulates the
balance of pro- versus anti-inﬂammatory cytokines [24]. In
this study, we examined the eﬀect of HLXL on speciﬁc
chemokines and MMPs, which play an important role in the
pathogenesis of AA [25]. As the expression/activity of certain
chemokinesaswellasMMPsisinﬂuencedsigniﬁcantlybythe
proinﬂammatory cytokines (IL-17 and IL-6), we also tested
the eﬀect of HLXL on these two cytokines. We observed that
HLXL treatment of arthritic rats attenuates the progression
of AA by inhibiting chemokines (RANTES, MCP-1, MIP-1α,
and GRO/KC), MMPs (MMP-2 and MMP-9), and cytokines
(IL-6andIL-17).Tothebestofourknowledge,thisistheﬁrst
report describing these HLXL-induced changes in arthritis.
2.MaterialsandMethods
2.1. Animals. Five- to six-week-old male Lewis (LEW/Hsd)
(RT.1l) rats were purchased from Harlan Sprague-Dawley
(HSD) (Indianapolis, IN, USA) and then maintained in
the animal care facility of the University of Maryland
School of Medicine, Baltimore. All experimental proce-
dures performed on these rats were in accordance with the
guidelines of the Institutional Animal Care and Use Com-
mittee (IACUC).
2.2. Composition and Characteristics of HLXL. The tradi-
tional Huo-Luo-Xiao-Ling Dan (HLXL) consists of four
herbs, namely, Danggui (Angelica sinensis (Oliv.) Diels),
Danshen (Salvia miltiorrhiza Bge.), Ruxiang (Boswellia car-
terii Birdw.), and Moyao (Commiphora myrrha Engl.). We
have previously reported [21–23] the rationale and the
nature of modiﬁcation of this original formula, and the
modiﬁed HLXL is a deﬁned mixture of 11 herbs, namely,
Ruxiang (Boswellia carterii Birdw.), Qianghuo (Notoptery-
gium incisum Ting ex H.T. Chang), Danggui (Angelica
sinensis (Oliv.) Diels), Baishao (Paeonia lactiﬂora Pall.),
Gancao (Glycyrrhiza uralensis Fisch.), Yanhusuo (Corydalis
yanhusuo W.T. Wang.), Danshen (Salvia miltiorrhiza Bge.),
Chuanxiong (Ligusticum chuanxiong S.H. Qiu.), Qin jiao
(Gentiana macrophylla Pall.), Guizhi (Cinnamomum cas-
sia Presl.), and Duhuo (Angelica pubescens Maxim). The
compounds isolated from HLXL include steroids, terpenes,
alkaloids,ﬂavonoids,glycosides,andacids[21].Themethods
for the preparation of HLXL, for the characteristics of its
component herbs, and for the assessment of its toxicity
have been described in detail elsewhere [22, 23]. As in our
earlier studies [23, 24] the batch of HLXL tested in this
study was thoroughly characterized by HPLC ﬁngerprinting,
which were characterized by the peak shapes, numbers,
intensities, and retention times of all individual compounds
(data not shown). Moreover, the marker compounds, swer-
tiamarin (from Gentiana macrophylla), osthole (Angelica
pubescens), paeoniﬂorin (Paeonia lactiﬂora), iso-imperatorin
(Notopterygium incisum), liquiritin (Glycyrrhiza uralensis),
columbianadin (Angelica pubescens), liquiritigenin (Gly-
cyrrhiza uralensis), falcarindiol (Notopterygium incisum),
angelol B (Angelica pubescens), cryptotanshinone (Salvia
miltiorrhiza),bergapten(Angelica pubescens),tanshinoneIIA
(Salvia miltiorrhiza), senkyunolide A (Ligusticum chuanx-
iong), ostruthin (Notopterygium incisum), phenethyl trans-
ferulate (N. incisum), and anhydronotoptol (N. incisum),
served as references for quality control purposes. In a recent
study [21], we reported that some of the above-mentioned
herbs other than the 4 traditionally used in classical HLXL,
possessed compounds that served as ligands for the enzyme
cyclo-oxygenase 2 (COX-2). This further reinforces in part
the rationale for the modiﬁcation of the original HLXL
formula.
2.3. Treatment of Arthritic Rats with HLXL. Lewis rats were
immunized subcutaneously (s.c.) with 1mg/rat heat-killed
M. tuberculosis H37Ra (Mtb) (Difco, Detroit, MI) in 200μL
of mineral oil (Sigma-Aldrich) at the base of the tail.
Following the onset of arthritis, these rats were randomly
divided into two groups (experimental and control). HLXL
was ﬁnely powdered and suspended in 200mL of water
using a pestle and mortar, and it was fed (2.3g/kg) to the
experimental group of rats using a gavage needle (FNC-16-3,
Kant Scientiﬁc Corporation, Torrington, CT, US) beginning
on the day of onset of arthritis (d 10) and then continuedEvidence-Based Complementary and Alternative Medicine 3
up to the peak phase of AA (d 18). On the corresponding
days, the control group of rats received water (the vehicle)
by gavage. All rats were examined and graded regularly for
the severity of arthritis as described earlier [24, 26]. The test
samples were collected from rats when the disease reached
the peak phase (d 18) in controls.
2.4. Preparation and Antigenic Restimulation of Lymph Node
Cells (LNC). Rats treated either with HLXL or with vehicle
(water) only were euthanized at the peak phase of AA (d
18) and their draining lymph nodes (para-aortic, inguinal
and popliteal) were harvested [26]. A single cell suspension
of LNC was prepared in HL-1 serum free medium (Ventrex
Laboratories, Portland, ME) supplemented with 2mM L-
glutamine, 100U/mL penicillin G sodium, and 100μg/mL
streptomycin sulfate. In each experiment, LNC from 3
rats were pooled for testing. These LNC were cultured (8
× 106 cells/well) in a 6-well plate (Corning Incorporated
Corning, NY) for 24h at 37◦C in an atmosphere of 95% air
and 5% CO2. Sonicated Mtb (10μg/mL) was used for res-
timulation of LNC. Keyhole limpet hemocyanin (KLH) was
used as the control antigen. Total RNA was prepared from
these LNC for testing by quantitative real-time polymerase
chain reaction (qRT-PCR) as described below. Alternatively,
the LNC culture supernatant was harvested for testing by a
Multiplex assay as elaborated below.
2.5. Spleen Adherent Cells (SAC) and Their Stimulation with
Sonicated Mtb. Spleens were harvested from experimen-
tal/control rats (n = 3 each) at the peak phase of AA (d 18)
and a single cell suspension was prepared as described above
for LNC. These spleen cells were allowed to settle in a 6-well
plate at 37◦C in RPMI medium supplemented with 5% fetal
bovineserum(FBS),2mMLglutamine,100U/mLpenicillin
Gsodium,and100μg/mLstreptomycinsulfate.After90min,
nonadherent cells were removed by washing with HBSS
(Invitrogen, Frederick, MD), yielding the SAC [27]. These
SAC (1.5–2.0 × 106 cells per well) were restimulated for 6h
with sonicated Mtb (10μg/mL). KLH served as the control
antigen. Thereafter, culture supernatants were collected for
testing in Multiplex assay. Alternatively, total RNA was
prepared from these SAC as described below.
2.6. Determination of Matrix Metalloproteinase (MMP)/
Cytokine mRNA Expression by qRT-PCR. RNA was isolated
from LNC and SAC using TRIzol reagent (Invitrogen,
Carlsbad,CA)andthencDNAwaspreparedfromRNAusing
iScript cDNA synthesis kit (Bio-Rad laboratories, Hercules,
CA). The resultant cDNA was ampliﬁed in an ABI Prism
7900HT cycler (Applied Biosystems) by qRT-PCR using
SYBR Green PCR Master Mix (Applied Biosystems) and
the appropriate primers for MMP-2, MMP-9, IL-6, and
IL-17. These primers were synthesized at the Biopolymer
Core Facility, University of Maryland, Baltimore. The mRNA
levels of the genes of interest were normalized to the
hypoxanthine-guanine phosphoribosyltransferase (HPRT)
gene, and the relative gene expression levels were expressed
as “fold increase” [26].
2.7. Determination of Chemokine/Cytokine Protein Expression
by Multiplex Suspension Bead Array Immunoassay. Multiplex
assays were performed at the Cytokine Core Facility (Univer-
sity of Maryland, Baltimore) using the Luminex 100 analyzer
(Luminex Corp., Austin, TX) and the level of cytokines (as
protein) in 24h culture supernatant of LNC and SAC were
measured. The Rat chemokine 4-plex kit (Millipore) was
used to measure RANTES, MCP-1, MIP-1α,a n dG R O / K C
and the Rat cytokine 2-plex kit was used to measure IL-6 and
IL-17.
2.8. Measurement of MMP Activity Using a Zymogram Assay.
The MMP activity in the culture supernatants of LNC and
SAC stimulated with or without Mtb was determined using
a zymogram assay as described previously [26, 28]. Brieﬂy,
culture supernatant was loaded onto a gelatin-coated, pre-
casted polyacrylamide gel (Bio-Rad). Electrophoresis was
carried out under SDS-nonreducing conditions at constant
voltage. The gel was incubated with 2.5% Triton X-100
at room temperature for 1-2h to remove SDS. The gel
was then washed 3-4 times with water to remove Triton
X-100 and incubated overnight at 37◦C in a developing
buﬀer (Tris-HCl, pH 7.4) containing 5mM CaCl2,0 . 2 M
NaCl, and 0.02% Brij 35. Thereafter, the gel was stained
with Coomassie Brilliant Blue R-250. Standard MMP-2
and MMP-9 (Sigma) were used as positive controls. The
MMP activity was visualized and scanned after destaining.
Thereafter, the intensity of the bands was quantitated by
densitometry using Image J software.
2.9. Statistical Analysis. T h ed a t aw e r ee x p r e s s e da sm e a n±
SEM. Student’s t-test and ANOVA were used to assess the
signiﬁcance of diﬀerences using GraphPad Prism version 4.0.
A P value of <0.05 was considered signiﬁcant.
3. Results
As reported earlier [24], we observed in this study that HLXL
treatment of arthritic Lewis rats reduced the severity of AA.
The mean arthritic score on d 18 (peak phase of AA), was
2.2 for HLXL-treated group compared to 4.6 for the control
water-treated group, and this diﬀerence was statistically
signiﬁcant (P<0.02). We then determined the eﬀect of
HLXL on speciﬁc chemokines, MMPs and cytokines on d
18 of arthritis and compared the results with those obtained
from the control rats. The results are presented below.
3.1. HLXL Treatment Downmodulates Chemokine Production
in Arthritic Lewis Rats. Chemokines and their receptors
coordinate the movement of cells of the immune system and
direct these cells to the site of inﬂammation. The antigen-
draining lymph nodes are the site of initial cellular activation
and interactions. In this context, we tested the eﬀect of
HLXL treatment on chemokines produced by the draining
LNC. Speciﬁcally, we tested for RANTES, MCP-1, MIP-
1α, and GRO/KC. These chemokines were measured in
culture supernatants of the draining LNC restimulated with
s o n i c a t e dM t bf o r2 4 h( Figure 1). We observed a 4.4-fold4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Suppression of chemokines in HLXL-treated arthritic rats. Lymph node cells (LNC) harvested at the peak phase of the disease
(d 18) from arthritic rats fed with HLXL or the vehicle (water) were cultured in vitro for 24h in the presence or absence of sonicated Mtb.
Thereafter, the culture supernatants were harvested and tested for chemokines: RANTES (a), MCP-1 (b), MIP-1α (c), and GRO/KC (d).
The results were expressed as Δpg/mL. Representative results of one of two independent experiments are shown (∗∗∗P<0.005) (Mtb =
heat-killed M. tuberculosis H37Ra).
decrease in RANTES in HLXL-treated group, which was
highly signiﬁcant (P<0.001) when compared to the control
group. There was a 2.1- and 1.6-fold decrease in MCP-1 (P<
0.00001) and MIP-1α (P<0.001), respectively after HLXL
treatment. GRO/KC showed a marked downregulation in
HLXL-treated group with a 4.5-fold decrease (P<0.001)
compared to the control group.
3.2.HLXLSuppressesMMP-9andMMP-2ActivityinArthritic
Rats. MMPs mediate the degradation of extracellular matrix
macromolecules, and they play an important role in car-
tilage and bone damage in arthritic joints. Therefore, to
further understand the mechanisms underlying the arthritis-
protective eﬀect of HLXL, we evaluated the mRNA expres-
sion and enzyme activity of MMPs in SAC that were har-
vested from HLXL-treated or control rats and then restim-
ulated with sonicated Mtb for 24h. Treatment with HLXL
caused a 1.7-fold decrease in the expression of MMP-9 but
no signiﬁcant change in MMP-2 mRNA expression (see Sup-
plementary Figure 1 in Supplementary material available
online atdoi: 10.1155/2012/589256). Furthermore,there was
2.3-fold suppression in the activity of MMP-9 and a 2.7-
fold decrease in MMP-2 activity in HLXL-treated group
compared to the controls (Figure 2).
3.3. HLXL Treatment Inhibits Antigen-Induced Pro-Inﬂam-
matory Cytokine Response in Arthritic Rats. IL-6 and IL-17
are proinﬂammatory cytokines that have a signiﬁcant eﬀect
on diﬀerent chemokines and MMPs involved in the arthrito-
genic processes. Therefore, we tested the levels of these two
cytokines (as proteins) in the draining LNC that were har-
vestedfromHLXL-treatedandcontrolarthriticratsandthen
restimulated in vitro for 24h with sonicated Mtb. There was
asigniﬁcant decreasein thelevelofIL-6(P<0.0002) andIL-
17 (P<0.0001) in HLXL-treated rats compared with water-
treated rats (Figures 3(a) and 3(b)). HLXL-treated groupEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: The eﬀect of HLXL on MMP activity in arthritic rats. Spleen adherent cells (SACs) harvested from rats fed with HLXL or the
vehicle (water) were stimulated for 24h with sonicated Mtb. The supernatants obtained from these cultured cells were analyzed for MMP-9
(a) and MMP-2 (b) activity using a zymogram assay. The results are representative of two independent experiments (Mtb = heat-killed M.
tuberculosis H37Ra).
showed a 1.8-fold decrease in IL-6 and a 4.3-fold de-crease
in IL-17 compared to the controls. Furthermore, in SACs
stimulated with sonicated Mtb, there was a 14 fold decrease
in IL-6 and a 3.4 fold reduction in IL-17 in HLXL-treated
rats compared to vehicle-treated rats (see Supplementary
Figure 2). Thus, HLXL inhibited cytokine production in
LNC as well as SAC, indicating a systemic eﬀect.
4. Discussion
In this study based on the rat AA model of human RA, we
observed that HLXL-treated rats had signiﬁcantly reduced
levels of chemokines (RANTES, MCP-1, MIP-1α,a n d
GRO/KC) as well as matrix-degrading enzymes, MMP2 and
MMP9. Also reduced were the levels of the proinﬂammatory
cytokines IL-6 and IL-17.
4.1. The Involvement of Chemokines in the Pathogenesis of
Arthritis and the Therapeutic Targeting of Chemokines. High
levels of RANTES are found in the synovial ﬂuid and serum
obtained from patients with RA, and it promotes the mi-
gration of mononuclear cells (including lymphocytes) from
blood vessels and synovial ﬂuid into the synovium [12].
MCP-1 is chemotactic for monocytes and T lymphocytes
[15] whereas GRO-α is a chemoattractant for neutrophils in
RA [13]. Elevated levels of MIP-1α are found in sera and
synovial ﬂuid of RA patients suggesting that MIP-1α plays
an important role in the progression of the disease [14].
Initial clinical trials on chemokine blockade in patients with
RA suggest that targeting the chemokine and chemokine
receptor family might provide a promising therapeutic
approach for this deliberating disease [10]. In this context,
the results of our study showing that the above-mentioned 4
chemokines are suppressed in HLXL-treated rats compared
to the controls are of high signiﬁcance.
In the AA model, high levels of RANTES are found in the
peripheral blood at the onset of the disease, whereas MCP-
1 is ﬁrst detected in the synovial tissue and later detected in
the peripheral blood on day 18 (peak phase of AA), when
joint inﬂammation is already very active [25]. These results
suggest that RANTES is essential for the initiation of the dis-
ease, whereas MCP-1 follows the disease onset. Blocking the
receptorforMCP-1beforetheonsetofarthritisinAAaﬀords
protection against the disease [29]. In our study reported
here, we observed a positive correlation between arthritic
scores and MCP-1 levels, with both being reduced after
HLXL treatment. Furthermore, our ﬁndings of suppression
of MCP-1 and RANTES after HLXL treatment are supported
by those of another study showing reduced serum levels of
MCP-1 and RANTES in RA patients following treatment
with formulations of dried encapsulated juice concentrate
[30]. Similarly, these chemokines can be suppressed by green
tea extract [31]. In regard to GRO/KC, it was shown in the
CIA model that this chemokine is elevated in the synovial6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Inhibition of proinﬂammatory cytokines in HLXL-treated arthritic rats. Lymph node cells (LNCs) harvested on d 18 (peak phase
of arthritis) from HLXL-fed or water-fed rats were cultured for 24h with or without sonicated Mtb. The culture supernatants were tested
for IL-6 (a) and IL-17 (b) using a multiplex assay. The results were expressed as Δpg/mL. The results are representative of two independent
experiments. (Mtb = heat-killed M. tuberculosis H37Ra).
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Figure 4: A schematic representation of the diverse mechanisms involved in HLXL-induced suppression of AA. HLXL attenuated arthritis
via suppressing the disease-regulating chemokines (regulated upon activation, normal T cell expressed and secreted: RANTES; monocyte
chemotactic protein-1: MCP-1; macrophage inﬂammatory protein-1α: MIP-1α; growth regulated oncogene-keratinocyte chemoattractant:
GRO/KC), matrix metalloproteinases (MMP-2 and MMP-9), and cytokines (IL-6 and IL-17). (S; spleen, L; lymph node, IJ; inﬂamed joint,
Mtb; heat-killed Mycobacterium tuberculosis H37Ra).
ﬂuid of arthritic rats and that its levels are reduced following
suppression of arthritis by an inhibitor of spleen tyrosine
kinase[32].Theresultsofourstudy intheAAmodelshowed
signiﬁcant suppression of GRO/KC in HLXL-treated rats,
which was associated with reduced severity of AA compared
to the control rats.
4.2. The Induction and Regulation of MMPs by Pro-Inﬂam-
matory Cytokines and Chemokines, and the Control of MMP
Activity for Therapeutic Purposes. Macrophages and ﬁbrob-
lasts synthesize and secrete several MMPs that participate in
the degradation of ECM components and contribute signif-
icantly to the tissue damage in RA [9]. Furthermore, MMP-9
is believed to play a key role in directing the migration of
macrophages and neutrophils in RA [8, 33]. Synovial ﬂuid
fromRApatientscontainshighlevelsofMMP-2andMMP-9
[16].Therefore,MMP-2andMMP-9areattractivetargetsfor
thetreatmentofRA[11]. In this context, our results showingEvidence-Based Complementary and Alternative Medicine 7
that HLXL decreases MMP-9 and MMP-2 activity in AA are
of direct relevance to RA.
Besides MMPs, the increased activity of the proin-
ﬂammatory cytokines such as IL-6 and IL-17 is closely
associated with the destruction of cartilage and bone in
RA. IL-6 stimulates the production of MMP-2 and MMP-9
[17]. IL-17 also enhances MMP-2 and MMP-9 expression
and is synergistic with IL-1β and TNF-α in inducing the
expression of other proinﬂammatory cytokines and MMPs
[8]. We observed that both IL-6 and IL-17 (as proteins) were
signiﬁcantly reduced after HLXL treatment. This is the ﬁrst
report on HLXL-mediated suppression of IL-6 in AA. In
addition, our study revealed the inhibitory eﬀect of HLXL
on IL-17 at the protein level, validating our earlier ﬁnding on
the reduction of IL-17 mRNA expression [24]. We suggest
that the downregulation of IL-6 and IL-17 had a signiﬁcant
inﬂuence, either directly or indirectly, on the MMP activity,
which was found to be decreased in HLXL-treated rats.
Chemokines also regulate the expression and activity of
MMPs. For example, RANTES and MCP-1 activate mono-
cytestosecreteTNF-α,andTNF-αinturnstimulatesMCP-1,
which then induces MMP-9 production by monocytes [34].
On the basis of our results, we suggest that HLXL-induced
reduction in MCP-1 might have contributed in part to the
reduced production of MMP-9.
4.3. The Bidirectional Interplay between Pro-Inﬂammatory
CytokinesandChemokines. OverproductionofIL-6isachar-
acteristic feature of RA, and inhibiting IL-6 activity is one of
the therapeutic options for treating RA. Other investigators
[35] have shown that RANTES and MCP-1 regulate IL-
6 production by ﬁbroblast-like synoviocytes in RA. These
observations support our results of HLXL-induced concur-
rent decrease in the above-referenced chemokines as well as
IL-6. The other prominent proinﬂammatory cytokine, IL-
17, stimulates the production of multiple chemokines such
as MCP-1 and GRO/KC [36] .I no u rs t u d y ,w eh a v es h o w n
the concurrent downregulation of chemokines and IL-17 in
HLXL-treated rats compared to the control rats.
In conclusion, HLXL acts on diﬀerent chemokines,
MMPs, and cytokines and suppresses their expression,
which in turn leads to attenuation of inﬂammatory arthritis
(Figure 4). The precise mechanisms of inhibition of these
mediatorsofinﬂammationarecurrentlyunderinvestigation.
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